Thursday, April 30, 2009

Fyterdin




Fyterdin may be available in the countries listed below.


Ingredient matches for Fyterdin



Terbinafine

Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Fyterdin in the following countries:


  • Mexico

International Drug Name Search

Tuesday, April 28, 2009

Ramipril Mepha




Ramipril Mepha may be available in the countries listed below.


Ingredient matches for Ramipril Mepha



Ramipril

Ramipril is reported as an ingredient of Ramipril Mepha in the following countries:


  • Portugal

International Drug Name Search

Sunday, April 26, 2009

Abilify


Abilify is a brand name of aripiprazole, approved by the FDA in the following formulation(s):


ABILIFY (aripiprazole - injectable; intramuscular)



  • Manufacturer: OTSUKA

    Approval date: September 20, 2006

    Strength(s): 9.75MG/1.3ML (7.5MG/ML) [RLD]

ABILIFY (aripiprazole - solution; oral)



  • Manufacturer: OTSUKA

    Approval date: December 10, 2004

    Strength(s): 1MG/ML [RLD]

ABILIFY (aripiprazole - tablet, orally disintegrating; oral)



  • Manufacturer: OTSUKA

    Approval date: June 7, 2006

    Strength(s): 10MG [RLD], 15MG

ABILIFY (aripiprazole - tablet; oral)



  • Manufacturer: OTSUKA

    Approval date: November 15, 2002

    Strength(s): 10MG [RLD], 15MG, 20MG, 2MG, 30MG, 5MG [RLD]

Has a generic version of Abilify been approved?


No. There is currently no therapeutically equivalent version of Abilify available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Carbostyril derivatives
    Patent 5,006,528
    Issued: April 9, 1991
    Inventor(s): Oshiro; Yasuo & Sato; Seiji & Kurahashi; Nobuyuki
    Assignee(s): Otsuka Pharmaceutical Co., Ltd.
    A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R.sup.1 is a C.sub.1- C.sub.3 alkoxy group)), a group of the formula ##STR3## ((wherein R.sup.2 and R .sup.3 are each, at the same time, a chlorine atom, a bromine atom; and R.sup.4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R.sup.5 is a chlorine atom or a bromine atom; and R.sup.6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond).
    Patent expiration dates:

    • October 20, 2014
      ✓ 
      Patent use: TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • October 20, 2014
      ✓ 
      Patent use: ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • April 20, 2015
      ✓ 
      Pediatric exclusivity




  • Aripiprazole oral solution
    Patent 6,977,257
    Issued: December 20, 2005
    Inventor(s): Parab; Prakash V. & Chou; Joyc Tianw i
    Assignee(s): Bristol-Myers Squibb Company
    The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
    Patent expiration dates:

    • April 24, 2022
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • October 24, 2022
      ✓ 
      Pediatric exclusivity




  • Aripiprazole complex formulation and method
    Patent 7,115,587
    Issued: October 3, 2006
    Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
    Assignee(s): Bristol-Myers Squibb Company
    An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Patent expiration dates:

    • July 21, 2024
      ✓ 
      Patent use: TREATMENT OF SCHIZOPHRENIA
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 21, 2025
      ✓ 
      Pediatric exclusivity




  • Aripiprazole complex formulation and method
    Patent 7,550,445
    Issued: June 23, 2009
    Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
    Assignee(s): Bristol-Myers Squibb Company
    An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Patent expiration dates:

    • July 21, 2024
      ✓ 
      Drug product


    • January 21, 2025
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 29, 2010 - TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17

    • November 16, 2010 - ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    • February 27, 2011 - TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

    • April 29, 2011 - PEDIATRIC EXCLUSIVITY

    • May 6, 2011 - STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

    • May 6, 2011 - ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

    • August 27, 2011 - PEDIATRIC EXCLUSIVITY

    • November 19, 2012 - TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE

    • February 16, 2014 - MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

See also...

  • Abilify Consumer Information (Drugs.com)
  • Abilify Consumer Information (Wolters Kluwer)
  • Abilify Solution Consumer Information (Wolters Kluwer)
  • Abilify Tablets Consumer Information (Wolters Kluwer)
  • Abilify Consumer Information (Cerner Multum)
  • Abilify Advanced Consumer Information (Micromedex)
  • Abilify Intramuscular Advanced Consumer Information (Micromedex)
  • Abilify AHFS DI Monographs (ASHP)
  • Aripiprazole Consumer Information (Wolters Kluwer)
  • Aripiprazole Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Aripiprazole Solution Consumer Information (Wolters Kluwer)
  • Aripiprazole Tablets Consumer Information (Wolters Kluwer)
  • Aripiprazole Consumer Information (Cerner Multum)
  • Aripiprazole Advanced Consumer Information (Micromedex)
  • Aripiprazole Intramuscular Advanced Consumer Information (Micromedex)
  • Aripiprazole AHFS DI Monographs (ASHP)

DBL Dexamethasone Sodium Phosphate




DBL Dexamethasone Sodium Phosphate may be available in the countries listed below.


Ingredient matches for DBL Dexamethasone Sodium Phosphate



Dexamethasone

Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of DBL Dexamethasone Sodium Phosphate in the following countries:


  • Australia

International Drug Name Search

Tuesday, April 21, 2009

Cistina Quimica Medica




Cistina Quimica Medica may be available in the countries listed below.


Ingredient matches for Cistina Quimica Medica



Cystine

Cystine is reported as an ingredient of Cistina Quimica Medica in the following countries:


  • Spain

International Drug Name Search

Friday, April 17, 2009

Iumizol




Iumizol may be available in the countries listed below.


Ingredient matches for Iumizol



Albendazole

Albendazole is reported as an ingredient of Iumizol in the following countries:


  • Peru

International Drug Name Search

Thursday, April 16, 2009

Flumidon




Flumidon may be available in the countries listed below.


Ingredient matches for Flumidon



Meloxicam

Meloxicam is reported as an ingredient of Flumidon in the following countries:


  • Greece

International Drug Name Search

Psipax




Psipax may be available in the countries listed below.


Ingredient matches for Psipax



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Psipax in the following countries:


  • Portugal

International Drug Name Search

Sunday, April 12, 2009

Vyvanse


Vyvanse is a brand name of lisdexamfetamine, approved by the FDA in the following formulation(s):


VYVANSE (lisdexamfetamine dimesylate - capsule; oral)



  • Manufacturer: SHIRE DEVELOPMENT

    Approval date: February 23, 2007

    Strength(s): 30MG, 50MG, 70MG [RLD]


  • Manufacturer: SHIRE DEVELOPMENT

    Approval date: December 10, 2007

    Strength(s): 20MG, 40MG, 60MG

Has a generic version of Vyvanse been approved?


No. There is currently no therapeutically equivalent version of Vyvanse available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyvanse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Abuse-resistant amphetamine compounds
    Patent 7,105,486
    Issued: September 12, 2006
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas
    Assignee(s): New River Pharmaceuticals Inc.
    The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)


    • June 29, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)




  • Abuse resistant lysine amphetamine compounds
    Patent 7,223,735
    Issued: May 29, 2007
    Inventor(s): Mickle; Travis & Krishnan; Suma & Moncrief; James Scott & Lauderback; Christopher & Bishop; Barney & Oberlender; Rob & Piccariello; Thomas
    Assignee(s): New River Pharmaceuticals Inc.
    The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,655,630
    Issued: February 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug substance




  • Abuse-resistant amphetamine prodrugs
    Patent 7,659,253
    Issued: February 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,659,254
    Issued: February 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS




  • Abuse resistant lysine amphetamine compounds
    Patent 7,662,787
    Issued: February 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Rob & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug substance




  • Abuse-resistant amphetamine prodrugs
    Patent 7,662,788
    Issued: February 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,671,030
    Issued: March 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,671,031
    Issued: March 2, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 28, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,674,774
    Issued: March 9, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 18, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,678,770
    Issued: March 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 25, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,678,771
    Issued: March 16, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • March 25, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,687,466
    Issued: March 30, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,687,467
    Issued: March 30, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • April 8, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,700,561
    Issued: April 20, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • June 29, 2023
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,713,936
    Issued: May 11, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)




  • Abuse-resistant amphetamine prodrugs
    Patent 7,718,619
    Issued: May 18, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product




  • Abuse-resistant amphetamine prodrugs
    Patent 7,723,305
    Issued: May 25, 2010
    Inventor(s): Mickle; Travis & Krishnan; Suma & Bishop; Barney & Lauderback; Christopher & Moncrief; James Scott & Oberlender; Robert & Piccariello; Thomas & Paul; Bernhard J. & Verbicky; Christopher A.
    Assignee(s): Shire LLC
    The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
    Patent expiration dates:

    • February 24, 2023
      ✓ 
      Patent use: INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 23, 2011 - NEW PATIENT POPULATION

    • February 23, 2012 - NEW CHEMICAL ENTITY

    • April 5, 2013 - LABELING REVISIONS RELATED TO CLINICAL STUDIES

    • November 10, 2013 - NEW PATIENT POPULATION

    • January 31, 2015 - MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

See also...

  • Vyvanse Consumer Information (Drugs.com)
  • Vyvanse Consumer Information (Wolters Kluwer)
  • Vyvanse Consumer Information (Cerner Multum)
  • Vyvanse Advanced Consumer Information (Micromedex)
  • Vyvanse AHFS DI Monographs (ASHP)
  • Lisdexamfetamine Consumer Information (Wolters Kluwer)
  • Lisdexamfetamine Consumer Information (Cerner Multum)
  • Lisdexamfetamine dimesylate Advanced Consumer Information (Micromedex)
  • Lisdexamfetamine Dimesylate AHFS DI Monographs (ASHP)

Saturday, April 11, 2009

Tetragen




Tetragen may be available in the countries listed below.


Ingredient matches for Tetragen



Tetracycline

Tetracycline hydrochloride (a derivative of Tetracycline) is reported as an ingredient of Tetragen in the following countries:


  • Bangladesh

International Drug Name Search

Tuesday, April 7, 2009

Bromhist-DM


Generic Name: brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine (brom fen EER a meen, DEX tro me THOR fan, gwye FEN e sin, SOO doe ee FED rin)

Brand Names: Bromhist-DM, Histacol DM Pediatric Syrup, Pediahist DM Syrup


What is Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.


Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex.


Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine is used to treat sneezing, runny or stuffy nose, cough, chest congestion, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold.


Dextromethorphan will not treat a cough that is caused by smoking, asthma, or emphysema.

Brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Ask a doctor or pharmacist before using any other cough, cold, allergy, or sleep medication. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine, decongestant, expectorant, or cough suppressant. This medication impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body. Drinking alcohol can increase certain side effects of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine. Dextromethorphan will not treat a cough that is caused by smoking, asthma, or emphysema.

What should I discuss with my healthcare provider before taking Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Do not use a cough or cold medicine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:


  • kidney disease;


  • diabetes;




  • glaucoma;




  • heart disease or high blood pressure;




  • diabetes;




  • a thyroid disorder;




  • emphysema or chronic bronchitis;




  • an enlarged prostate; or




  • problems with urination.




This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially sweetened liquid cough or cold medicine may contain phenylalanine. If you have phenylketonuria (PKU), check the medication label to see if the product contains phenylalanine.


How should I take Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Take this medicine with a full glass of water. Do not crush, chew, or break an extended-release tablet. Swallow the pill whole. Breaking or opening the pill would cause too much of the drug to be released at one time.

Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash.

If you need surgery, tell the surgeon ahead of time if you have taken a cold medicine within the past few days.


This medication can cause you to have unusual results with allergy skin tests. Tell any doctor who treats you that you are taking an antihistamine.


Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Since brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include feeling restless or nervous, nausea, vomiting, stomach pain, dizziness, drowsiness, dry mouth, warmth or tingly feeling, or seizure (convulsions).


What should I avoid while taking Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Ask a doctor or pharmacist before using any other cough, cold, allergy, or sleep medication. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains an antihistamine, decongestant, expectorant, or cough suppressant. This medication impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine.

Avoid taking diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • slow, shallow breathing;




  • confusion, hallucinations, unusual thoughts or behavior;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure);




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms; or




  • urinating less than usual or not at all.



Less serious side effects may include:



  • dry mouth;




  • nausea, stomach pain, constipation, mild loss of appetite, upset stomach;




  • blurred vision;




  • warmth, tingling, or redness under your skin;




  • sleep problems (insomnia);




  • feeling restless or excited (especially in children);




  • skin rash or itching;




  • dizziness, drowsiness, or headache;




  • problems with memory or concentration; or




  • ringing in your ears.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Bromhist-DM (brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine)?


Before taking this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by brompheniramine, dextromethorphan, or guaifenesin.

Tell your doctor about all other medications you use, especially:



  • a diuretic (water pill), or blood pressure medicine;




  • medication to treat irritable bowel syndrome;




  • bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol), darifenacin (Enablex), or tolterodine (Detrol);




  • aspirin or salicylates (such as Disalcid, Doan's Pills, Dolobid, Salflex, Tricosal, and others);




  • a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol (Blocadren), and others; or




  • antidepressants such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.



This list is not complete and other drugs may interact with brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Bromhist-DM resources


  • Bromhist-DM Side Effects (in more detail)
  • Bromhist-DM Use in Pregnancy & Breastfeeding
  • Bromhist-DM Drug Interactions
  • Bromhist-DM Support Group
  • 0 Reviews for Bromhist-DM - Add your own review/rating


  • Bromhist-DM Syrup MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Bromhist-DM with other medications


  • Cold Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about brompheniramine, dextromethorphan, guaifenesin, and pseudoephedrine.

See also: Bromhist-DM side effects (in more detail)


Saturday, April 4, 2009

Dutoprol


Dutoprol is a brand name of hydrochlorothiazide/metoprolol, approved by the FDA in the following formulation(s):


DUTOPROL (hydrochlorothiazide; metoprolol succinate - tablet, extended release; oral)



  • Manufacturer: ASTRAZENECA

    Approval date: August 28, 2006

    Strength(s): 12.5MG;EQ 100MG TARTRATE, 12.5MG;EQ 25MG TARTRATE, 12.5MG;EQ 50MG TARTRATE

Has a generic version of Dutoprol been approved?


No. There is currently no therapeutically equivalent version of Dutoprol available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dutoprol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Dutoprol.

See also...

  • Metoprolol/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide and metoprolol Consumer Information (Cerner Multum)
  • Metoprolol and hydrochlorothiazide Advanced Consumer Information (Micromedex)

Lasix Retard




Lasix Retard may be available in the countries listed below.


Ingredient matches for Lasix Retard



Furosemide

Furosemide is reported as an ingredient of Lasix Retard in the following countries:


  • Austria

  • Sweden

International Drug Name Search

Thursday, April 2, 2009

Tobramicina Normon




Tobramicina Normon may be available in the countries listed below.


Ingredient matches for Tobramicina Normon



Tobramycin

Tobramycin sulfate (a derivative of Tobramycin) is reported as an ingredient of Tobramicina Normon in the following countries:


  • Spain

International Drug Name Search